Please login to the form below

Not currently logged in
Email:
Password:

Rubraca

This page shows the latest Rubraca news and features for those working in and with pharma, biotech and healthcare.

AZ and Clovis PARP inhibitors show their mettle at ESMO

AZ and Clovis PARP inhibitors show their mettle at ESMO

AZ and Clovis PARP inhibitors show their mettle at ESMO. Lynparza and Rubraca both on track to extend cancer patient reach. ... extend its lead over its PARP inhibitor rivals, Tesaro's Zejula (niraparib) and Clovis' Rubraca (rucaparib).

Latest news

More from news
Approximately 6 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Among the noteworthy approvals are Lartruvo (for the treatment of soft tissue sarcoma, approved in the EU and US), Rubraca (for the treatment of ovarian cancer, only approved in the US),

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics